Expert Interviews

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

A patient case anchors this discussion of frontline management for de novo metastatic RCC with bulky, symptomatic disease.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

After progression on frontline immunotherapy-based combinations, patients with advanced RCC have a growing set of options.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how to interpret MRD negativity and progression-free survival (PFS) findings from the EXCALIBER-RRMM trial alongside results from established triplet regimens in relapsed/refractory multiple myeloma.

In this segment, Dr. Yuan Yuan reviews the phase 3 ASCENT-03 trial evaluating first-line sacituzumab govitecan (SG) versus investigator’s choice of chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) who were not candidates for immune checkpoint inhibitors.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.

In this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.

In this segment, the expert panel discusses the clinical implications of TROPION-Breast02 and the potential role of datopotamab deruxtecan (Dato-DXd) in first-line treatment of metastatic triple-negative breast cancer (TNBC) when immunotherapy is not an option.

Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.

At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.

Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute argues that the regimens patients navigate successfully in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC) are the ones their clinicians are comfortable managing.

Moshe C. Ornstein, MD, MA, of Cleveland Clinic explains to Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center why bone metastases do not drive his first-line regimen choice in advanced renal cell carcinoma (RCC).

Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center notes that subcutaneous amivantamab is given over roughly 5 minutes with fewer administration-related reactions, which matters at satellite sites, and that the weekly loading month creates repeated chances to reinforce skin care and antibiotic teaching in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC).

Terence W. Friedlander, MD, of UCSF Helen Diller Family Comprehensive Cancer Center tells Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center that simply counting metastatic sites is not a helpful way to assign first-line therapy in advanced renal cell carcinoma (RCC), unless a single site can be removed or irradiated.

Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.

At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.

At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.

At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.

At The Liver Meeting 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

The CLEAR trial established lenvatinib plus pembrolizumab as a frontline option in advanced RCC.

Selecting first-line therapy for advanced clear cell renal cell carcinoma (RCC) increasingly starts with a choice between dual immunotherapy and an immunotherapy plus tyrosine kinase inhibitor (TKI) combination.